3 Reasons Growth Investors Will Love Phibro (PAHC)

Core Viewpoint - Growth investors are increasingly interested in stocks with above-average financial growth, but identifying such stocks can be challenging due to their inherent risks and volatility. Phibro Animal Health (PAHC) is highlighted as a promising growth stock based on its favorable metrics and rankings [1][2]. Group 1: Earnings Growth - Phibro's historical EPS growth rate is 0.9%, but projected EPS growth for this year is expected to be 35.7%, significantly higher than the industry average of 19.6% [4]. Group 2: Asset Utilization - The company's asset utilization ratio (sales-to-total-assets ratio) is 1.07, indicating that Phibro generates $1.07 in sales for every dollar in assets, outperforming the industry average of 0.6 [5]. Group 3: Sales Growth - Phibro's sales are projected to grow by 15.7% this year, compared to the industry average of 5.6%, showcasing strong sales growth potential [6]. Group 4: Earnings Estimate Revisions - The current-year earnings estimates for Phibro have been revised upward, with the Zacks Consensus Estimate increasing by 0.2% over the past month, indicating positive momentum [7]. Group 5: Overall Assessment - Phibro has achieved a Growth Score of A and holds a Zacks Rank of 2 due to positive earnings estimate revisions, suggesting it is a solid choice for growth investors [9].